Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922724 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
A Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
- 2
- Study locations
NCT03922724: Recruiting Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, sponsored by National Cancer Institute (NCI).
NCT03922724 is a Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 330 participants, above the 134-participant average among 18 other Immune System Diseases trials with a reported enrollment target (146% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03922724, a Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of getting a recipient ready for a transplant may result in fewer problems and side effects. Eligibility: Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to standard treatments Donors: Healthy people ages 18 and older whose relative has lymphoma Design: Participants will be screened with: Physical exam Blood and urine tests Bone marrow biopsy: A needle inserted into the participant s hip bone will remove marrow. Donors will also be screened with: X-rays Recipients will also be screened with: Lying in scanners that take pictures of the body Tumor sample Donors may donate blood. They will take daily shots for 5 7 days. They will have apheresis: A machine will take blood from one arm and take out their stem cells. The blood will be returned into the other arm. Recipients will be hospitalized at least 2 weeks before transplant. They will get a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter. Recipients will stay in the hospital several weeks after transplant. They will get blood transfusions. They will take drugs including chemotherapy for about 2 months. Recipients will have visits 6, 12, 18, 24 months after transplant, then once a year for 5 years.
Primary Outcome
Number of patients who are alive and with PFS at one year, assessed by Kaplan-Meier with 80% and 95% two-sided confidence intervals
Conditions Studied
Interventions
- DRUG ATL-RIC
- DRUG mRIC
- PROCEDURE allo HCT
- DRUG RIC
- DRUG GVHD prophylaxis
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Minnesota
- National Marrow Donor Program - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2030-10-31 |
| Phase | Phase 2 |
What NCT03922724 shows while recruiting
NCT03922724 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 18 other Immune System Diseases trials with a reported enrollment target (146% higher).
The record links to 3 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 5 interventions - of which ATL-RIC is the first listed.
NCT03922724 reports a single indexed study location in Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03922724 about?
NCT03922724 is a clinical study titled "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma". Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of gettin...
What is the current status of trial NCT03922724?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2019-04-18. Estimated completion is 2030-10-31.
What conditions does trial NCT03922724 study?
This clinical trial studies the following conditions: Immune System Diseases, Lymphoproliferative Disorders, Peripheral T-cell Lymphomas.
What interventions are being tested in trial NCT03922724?
The interventions under investigation include: ATL-RIC (DRUG), mRIC (DRUG), allo HCT (PROCEDURE), RIC (DRUG), GVHD prophylaxis (DRUG).
Who is sponsoring clinical trial NCT03922724?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922724 being conducted?
This trial has 2 study locations across Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03922724's enrollment target sits among peer trials
330 4th of 18 higher than 15 of 18 other Immune System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immune System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
ACTIVE NOT RECRUITING · Phase 2
-
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
- NCT04900818 · 330 participants · Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI